8Fukumotoa JS, Greenberg PL. Management of patients with higher risk myelodysplastic syndromes. Cri Rev Oncol/Hematol, 2005, 56(2):179-192.
9Steensma DP, Tefferi A. The myelodysplastic syndrome (s): a perspective and review highlighting current controversies. Leuk Res, 2003,27(9) :95-120.
10Greenberg P, Cox C, Le Beau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997, 89(6) :2079-2088.
2Cheson BD,Bennett JM,Kantarjian H,et al.Report of an international working group to standardize response criteria for myelodysplastic syndromes[].Blood.2000
3N sslinger T,Reisner R,Koller E,et al.Myelodysplastic syndromes,from French-Americam-British to World Health Organization: comprison of classification on 431 unselected patients from a single institute[].Blood.2001
4Bennett JM.World Health Organization classification of the acute leukemias and myelodysplastic syndrome[].International Journal of Hematology.2000
5Harris NL,Jaffe ES,Diebold T,et al.World Health Orgnization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House,Virginia, November 1997[].Journal of Clinical Oncology.1999
6Greenberg P,Cox C,LeBeau MM,et al.International scoring system for evaluating prognosis in myelodysplastic syndromes[].Blood.1997
10Amiel A, Yukla M, Yogev S, et al. Deletion of 5q31 and 7q31 in patients with stable melphalan-treated multiple myeloma. Cancer Genet Cytogenet, 2004, 152 : 84-87.
